Marijuana (Cannabis):
Strains for Pain
Pain is the most frequently cited motivation for medical use of marijuana. There is an ongoing search for the “best” cannabis strains to use for pain. This section explores current information regarding specific marijuana strains and their purported benefits for managing pain.
Links to other Pertinent Educational Pages:
The medical information on this site is provided as a resource for information only, and is not to be used or relied upon for any diagnostic or treatment purposes and is not intended to create any patient-physician relationship. Readers are advised to seek professional guidance regarding the diagnosis and treatment of their medical concerns.
Key to Links:
- Grey text – handout
- Red text – another page on this website
- Blue text – Journal publication
This Page:
Strains:
.
Cannabis strains beneficial for pain
While there are no rules, users tend to report more effective pain-relief with indica strains. In one survey, participants reported that indicas helped more than sativas when it came to headaches, joint pain, neuropathy, and spasticity. Users also reported indicas to be more helpful when it comes to sleep and sedation. While sativa-dominant strains don’t seem as popular for pain management, they tend to have less sedative effects compared to indica strains.
However, over the several decades of widespread cannabis breeding, the ability to distinguish indica strains from sativa strains has become vague and unreliable with many hybrids now on the market. As such, it is important to evaluate the terpene profiles of individual candidate strains for pain, not just the the THC and CBD contents. While the total content and ratio of THC and CBD are major factors in pain benefit, it is largely the terpene and the minor cannabinoid profiles that distinguish one strain from another regarding a strain’s benefits and side effects.
Starting Points
THC
THC is the major contributor to pain relief associated with cannabis. Therefore most if not all strains with THC will offer at least some benefit for pain. A few key points need to be made. The dose of THC needed for pain varies significantly from individual to individual and depends on many factors, especially the individual’s tolerance based on time length of use. Few studies are available that isolate THC dosing for pain.
THC doesn’t simply work by directly reducing pain severity but instead it strongly influences the individual’s cognitive response to the pain (i.e. emotion, mood, memory etc.) to allow greater coping, relaxation and relief of pain. Therefore the other variables at play – CBD and terpenes – are very important in the ultimate response to cannabis for pain.
THC and CBD
It has been established that THC works better for pain with CBD. Recommendations for the ratio of the two are not exact but an equal amount of CBD and THC is a general starting point for pain. Higher doses of CBD, up to 8:1 or 10:1 ratios CBD:THC are recommended to reduce the side effects of THC and enhance anxiety and sleep benefits. Unfortunately, the flowers and vape products offered by LA pharmacies do not provide any CBD except for one vape product: “Freedom” by Ilera.
Terpenes
The following terpenes are most commonly recognized for their benefits for pain:
However, the evidence for these terpenes is weak but probably best for Beta-Caryophyllene and Myrcene (especially for headaches), followed by Limonene and Linalool. Pinene and Limonene tend to be stimulating wheras Linalool and Myrcene are sedating.
Anecdotal Reports – Chronic Pain
Upon review of many websites offering anecdotal reports regarding which cannabis strains are best for chronic pain, the following strains seem to be most popular for treating chronic pain. Future efforts will be directed at identifying strain benefits for specific chronic painful conditions including arthritis, fibromyalgia, headaches, nerve pain (neuropathies etc.) and visceral pain (IBS, Crohns, Interstitial Cystitis etc). Due to limitations of strain availability in Louisiana, those strains offered by the Louisiana dispensary pharmacies are listed first.
Blue Dream
Blue Dream is a blend of Blueberry (indica) with Haze (sativa) to create a sativa-dominant hybrid for treating pain. Blue Dream offers full-body relaxation with mental alertness and is reportedly effective for managing chronic pain without excessive sedation. Blue Dream has a reputation for being one of the best strains for relieving migraine headaches. It is also reported to improve depression and nausea. The THC content of Blue Dream ranges between 17-24% while its CBD content consistently ranges only from 0.1-0.2%. Its sweet berry aroma suggests prominent terpenes.
Blue Dream terpene profile (from industrialhempfarms.com):
Linalool (1.86%), alpha-Pinene (0.68%), Caryophyllene Oxide (0.40%), Caryophyllene (0.11%), Humulene (0.02%), Myrcene (<0.01%), beta-Pinene (<0.01%), Limonene (<0.01%), Terpinolene (<0.01%).
Total Terpenes: 3.07%
Terpene product: Blue Dream Natural Terpene Blend
Harlequin
Harlequin is sativa-dominant but very high in CBD with less than 10% THC, so there is less brain fog and euphoria while the CBD works on pain issues. Harlequin is considered by many to be the most effective for arthritis pain and also good for fibromyalgia and nerve pain, muscle and joint pain, menstrual cramps and nausea.
Harlequin terpene profile (from industrialhempfarms.com):
alpha-Pinene (0.309%), Myrcene (0.298%), Caryophyllene (0.238%), beta-Pinene (0.099%), Humulene (0.082%), Limonene (0.058%), Linalool (0.010%), Terpinolene (<0.002%), Ocimene (<0.002%).
Total Terpenes: 1.094%
Terpene product: Harlequin Natural Terpene Blend
Kush Strains (especially Master Kush)
There are many different varieties of Kush,” including purple Kush, OG Kush, Hindu Kush, and Bubba Kush to name some of the popular ones. Most of these strains are indica-based, originating from the Hindu Kush area of the Himalayas. Most are high in THC content. Master Kush is considered very potent. Bubba Kush is commonly found to be effective for pain, stress and depression, and is thought to be very effective for insomnia. The THC content of Bubba Kush ranges from 14-22%, and the CBD content ranges from 0.06-0.1%. Redwood Kush is known for its muscle relaxation properties. Afghan Kush is reported to be very effective for nerve pain but can be very sedating and it has a high CBD content.
OG Kush terpene profile (from industrialhempfarms.com):
Humulene (0.97%), alpha-Pinene (0.63%), Caryophyllene (0.34%), Terpinolene (0.10%), Myrcene (0.08%), Linalool (<0.01%), Caryophyllene oxide (0.96%), beta-Pinene (<0.01%), Limonene (<0.01%).
Total terpenes 2.13%
Terpene product: OG Kush Natural Terpene Blend
Hindu Kush terpene profile (from industrialhempfarms.com):
Humulene (0.66%), alpha-Pinene (0.26%), Caryophyllene (0.61%), Terpinolene (<0.01%), Myrcene (0.09%), Linalool (<0.01%), Caryophyllene oxide (<0.01%), beta-Pinene (<0.01%), Limonene (<0.01%).
Total terpenes 2.57%
Bubba Kush terpene profile (from industrialhempfarms.com):
Humulene (1.76%), Linalool (1.46%), Caryophyllene oxide (0.62%), Caryophyllene (0.4%), alpha-Pinene (<0.01%), Terpinolene (<0.01%), Myrcene (<0.01%), beta-Pinene (<0.01%), Limonene (<0.01%).
Total terpenes 4.24%
AK-47
A sativa-dominant hybrid strain, AK-47 is a popular strains for treating chronic pain. It is reported to be derived from a variety of different strains, including South American, Mexican, and Thai sativa strains and the Afghani indica strain. While it derived from both sativa and indica, AK 47 is sativa dominant, and likely to be energizing. The terpenes in AK-47 are reported to consist mainly of Myrcene, Caryophyllene, d-Limonene, D-Alpha-Pinene, Alpha-Pinene and Beta-Pinene.
Terpene product: AK-47 Natural Terpene Blend
Jack Herer
Jack Herer is a cross between Shiva Skunk, Northern Lights #5 and a Haze hybrid that is sativa-dominant. It originated in the Netherlands in the 1990s, Jack Herer offers analgesia but less sedation than many of the indica-based strains. The THC content of Jack Herer ranges from 18-23%, and the CBD content ranges from 0.03 -0.2%. The terpenes in Jack Herer include pinene.
Terpene product: Jack Herer Natural Terpene Blend
OG Shark
OG Shark appears to be a lesser-known cannabis strain but in a study evaluating headache and chronic pain that is reviewed below, it ranked highest in preference by patients for treatment of chronic headaches and chronic pain.
Cannabinoids:
THC (21-25%), THCA (22.8%), CBD (<0.1%), CBDA (0.1%)
Terpenes:
β-Caryophyllene (0.263%), β-Myrcene (0.194%), D-Limonene (0.191%), Linalool (0.136%), Bisabolol (0.107%), Humulene (0.078%), Trans-Nerodiol (0.023%), α-Pinene (0.022%)
ACDC
ACDC has mixed reports of containing high levels of CBD but low levels of THC or high levels of both. It tends to produce little to no noticeable euphoria, or “high,” suggesting that the THC content is low. It helps to relieve pain and control stress.
ACDC terpene profile (from industrialhempfarms.com):
alpha-Pinene (<0.01%), Myrcene (<0.01%), Caryophyllene (<0.01%), beta-Pinene (<0.01%), Humulene (<0.01%), Limonene (<0.01%), Linalool (<0.01%), Caryophyllene Oxide (<0.01%), , Terpinolene (<0.01%). Total Terpenes: <0.01%
Terpene product: ACDC profile (from trueterpenes.com) with prominent alpha-Pinene and Myrcene
White Widow
White Widow is a potent, balanced sativa/indica hybrid strain, blending South American sativa and South Indian indica and is widely believed to be useful for chronic pain. Emerging in the Netherlands in the 1990s, the strain gained popularity in Dutch coffee houses. Many people believe this is one of the best choices for migraine headaches and is considered very effective for sleep. Its terpene profile is reported to include nerolidol (trans-nerolidol), limonene, myrcene, linalool and caryophyllene. One source identifies the following breakdown of the terpenes in White Widow where it is notable that this breakdown does not include nerolidol (trans-nerolidol), suggesting a lack of consistency in reports of cannabis strain constituents.
White Widow terpene profile (from industrialhempfarms.com):
Linalool (3.78%), alpha-Pinene (0.521%),, Myrcene (0.43%), Caryophyllene oxide (0.30%), Humulene (0.09%.beta-Pinene (<0.01%), Limonene (<0.01%), Terpinolene (<0.01%).
Total Terpenes 5.49%
Terpene product: White Widow Natural Terpene Blend
Research Evaluating Cannabis Strains for Pain
2018: Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort
This study conducted an electronic survey of 2032 medicinal cannabis patients, including those treating headache, arthritis, and chronic pain. The study evaluated demographics and patterns of cannabis use including methods, frequency, quantity, preferred strains, cannabinoid and terpene profiles. 21 illnesses were treated with cannabis and pain syndromes accounted for 42.4% (n = 861) overall; chronic pain 29.4% (n = 598;), arthritis 9.3% (n = 188), and headache 3.7% (n = 75;). Across all 21 illnesses, headache was a symptom treated with cannabis in 24.9% (n = 505), and 88% (n = 445) of headache patients were probable migraine.
Results:
-
- Hybrid strains were most preferred across all pain subtypes, with “OG Shark” the most preferred strain in the headache groups. When compared to insomnia/sleep disorder patients, headache as primary illness patients were 7.7 times as likely to prefer 3:1 CBD:THC over Indica
- Indica strains were preferred by the arthritis group
- Indica strains were preferred by the insomnia/sleep disorders group
- Sativa strains in the mental health condition/PTSD group
- Hybrid strains in the gastrointestinal disorder/Crohn’s Disease group
The preferred types of cannabis included Indica, Sativa, Hybrid, 3:1 CBD:THC, or 1:1 CBD:THC. Indicas, Sativas and Hybrids were all high THC/low CBD strains, while 1:1 and 3:1 strains and extracts represent the CBD:THC ratio, and were considered high CBD strains. The Indica, Sativa, and Hybrid types were further divided into specific strains within each of these cannabis types.
42 Preferred Strains
There were 42 different preferred treatment strains reported by patients and these included: Afghani, Afghani CBD, Alien OG, Barbara Bud, Black Tuna, Blueberry, Bubba Kush, Cannatonic, CBD House Blend, Cheese, Churchill, Dig Weed, Elwyn, Green Cush, Girl Scout Cookies (GSC), Harmony, Headband, Hybrid House Blend, Indica House Blend, Island Sweet Skunk, Jack Herer, Jean Guy, Lemon Sour Diesel, Limonene House Blend, Mango, Master Kush, Myrcene Blend, OG Kush, OG Shark, Pinene House Blend, Pink Kush, Purple Kush, Rockstar, Sativa House Blend, Sirius, Strawberry Cough (SBC), Skywalker OG, Sour Diesel, Sweet Skunk CBD, Warlock CBD, Watermelon, and White Widow.
Replacement of Prescription Medications with Marijuana
Many pain patients substituted prescription medications with cannabis (41.2–59.5%), most commonly opiates/opioids (40.5–72.8%). Prescription substitution in headache patients included opiates/opioids (43.4%), anti-depressant/anti-anxiety (39%), NSAIDs (21%), triptans (8.1%), anti-convulsants (7.7%), muscle relaxers (7%), ergots (0.4%).
Headache Group Preferences
-
- Hybrid – 26 (34.7%)
- Indica – 19 (25.3%)
- Sativa – 20 (26.7%)
- 3:1 CBD:THC – 5 (6.7%)
- 1:1 CBD:THC – 5 (6.7%)
- No response – 0 (0%)
Headache Strain Preferences
Headache as primary illness, predominantly migraine:
-
- Skywalker OG (7; 10.6%)
- Headband (5; 7.6%)
- Cannatonic (5; 7.6%)
- Jack Herer (5; 7.6%)
- Afghani (4; 6.1%)
- Indica House Blend (4; 6.1%)
- Rock Star (4; 6.1%)
In this study, of the top 15 strains effective for migraine headaches, all except two had myrcene contents ranging from 0.1% – 0.29%, with two outliers: 0.033% and 0.61%. It is suggested that cannabis strains such as OG Shark with myrcene and Β-caryophyllene may offer the best alternative combination for treating pain and headaches.
Resources:
National Academy of Sciences
These lay-person websites appear to be good resources for exploring medical marijuana. However, as is the case generally regarding medical applications of marijuana and its constitnuents, there is a huge amount of information that is not based in good science and relies on anecdotal (word-of-mouth) evidences. Reader, beware:
- www.CannabisBusinessTimes.com
- www.CBDschool.com
- www.gfarma.news
- www.GreenCamp.com
- www.Healer.com
- www.Marijuana.com
- www.MedicalJane.com
- www.profofpot.com
- www.ProjectCBD.org
- www.Weedmaps.com
References:
Medical Marijuana – Strains for Pain
Medical Marijuana – Chronic Pain
- A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis – 2016
- A tale of two cannabinoids – The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. 2005
- Cannabinoids for medical use – a systematic review and meta-analysis. – 2015
- Cannabinoids for the Treatment of Chronic Pain – A Critical Review of Randomized Controlled Trials – 2018
- Cannabinoids for treatment of chronic non-cancer pain – 2011
- Cannabinoids for Treatment of Chronic Non-Cancer Pain – a Systematic Review of Randomized Trials*
- Cannabinoids in Pain Management and Palliative Medicine – 2017
- Cannabis and intractable chronic pain – an explorative retrospective analysis of Italian cohort of 614 patients – 2017
- Cannabis and Pain – A Clinical Review – 2017
- Cannabis-based medicines for chronic neuropathic pain in adults (Review) – 2018
- Cannabis-based medicines for chronic neuropathic pain in adults. 2018 – PubMed – NCBI
- Cannabis—A Valuable Drug That Deserves Better Treatment – 2012
- Efficacy, tolerability and safety of cannabinoids in chronicpain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis) – 2016
- Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management – An overview of systematic reviews.2018 – PubMed – NCBI
- Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases – A Systematic Review of Randomized Controlled Trials – 2016
- Journal of Pain.Cannabis in Pain Treatment-Clinical and Research Considerations
- Medical Cannabis and Pain – IASP 2014
- Medical Cannabis for Non-Cancer Pain – A Systematic Review
- Medical cannabis associated with decreased opiate medication use in retrospective cross-sectional survey of chronic pain patients. 2016 – PubMed – NCBI
- Pharmacologic management of chronic neuropathic pain Review of the CanadianPain Society consensus statement- 2017
- Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain – 2018
- Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis – 2018
- Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis. – PubMed – NCBI
- Systematic review of systematic reviews for medical cannabinoids – 2018
- The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms – A Systematic Review – 2017
- The Endocannabinoid System, Cannabinoids, and Pain – 2013
- Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol – 2015
- Multicenter Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain – 2010
- Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study – 2017
Cannabis and Pain – Systematic Reviews
- Cannabis and Pain – A Clinical Review – 2017
- Cannabis-based medicines for chronic neuropathic pain in adults (Review) – 2018
- Cannabinoids for the Treatment of Chronic Pain – A Critical Review of Randomized Controlled Trials – 2018
- Cannabinoids for Treatment of Chronic Non-Cancer Pain – a Systematic Review of Randomized Trials*
- Cannabinoids in Pain Management and Palliative Medicine – 2017
- Systematic reviews on therapeutic efficacy and safety of Cannabis (including extracts and tinctures) – 2016
- Cannabinoids for treatment of chronic non-cancer pain – 2011
- Cannabinoids for medical use – a systematic review and meta-analysis. – 2015
- Medical Cannabis for Non-Cancer Pain – A Systematic Review
- The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. – PubMed – NCBI – 2017
- Cannabinoids, cannabis, and cannabis-based medicine for pain management – a systematic review of randomised controlled trials -2021
- Effects of Cannabinoid Administration for Pain – A Meta-Analysis and Meta-Regression – 2019
Medical Marijuana, Chronic Pain – Cannabinoids & Agmatine
- Agmatine co-treatment attenuates allodynia and structural abnormalities in cisplatin-induced neuropathy in rats. – PubMed – NCBI
- Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy. – 2018
- Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study – 2017
Medical Marijuana, Chronic Pain – Cannabinoids & Palmitoylethanolamide
- Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions – a case series – 2012
- Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent – 2013
- Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis – 2015
- Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol,… – PubMed – NCBI 2001
- Endocannabinoid-related compounds in gastrointestinal diseases – 2018
- ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors – 2008
- Medical Cannabis and Cannabinoids- An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon? – 2018
- Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide – 2001
- Phytocannabinoids beyond the Cannabis plant – do they exist? – 2010
- Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in c… – PubMed – NCBI
- Cannabinoids as pharmacotherapies for neuropathic pain – from the bench to the bedside. – 2009
- Correction – Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrome – 2018
- Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity – involvement of the CB2 receptor – 2017
- Mast cells, glia and neuroinflammation – partners in crime? – 2013
- A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia – A Review – 2018
Medical Marijuana – Opioids
- Use-of-Prescription-Pain-Medications-Among-Medical-Cannabis-Patients
- It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis – 2018
- Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort – 2018
- Patterns and correlates of medical cannabis use for pain among patients prescribed long-term opioid therapy. – PubMed – NCBI
- Associations between medical cannabis and prescription opioid use in chronic pain patients – A preliminary cohort study – 2017
- The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. – PubMed – NCBI
- The use of cannabis in response to the opioid crisis: A review of the literature. – PubMed – NCBI
- Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999–2010 – 2014
- Rationale for cannabis-based interventions in the opioid overdose crisis – 2017
- Cannabis and the Opioid Crisis – 2018
- Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. – PubMed – NCBI
- Cannabinoid–Opioid Interaction in Chronic Pain
- Synergistic interactions between cannabinoid and opioid analgesics. – PubMed – NCBI
- FDA approves CBD drug – Epidiolex – The Washington Post
- Effect of cannabis use in people with chronic non-cancer pain prescribed opioids – findings from a 4-year prospective cohort study – 2018
Medical Marijuana – THC, Oral
Medical Marijuana – Pain
- Use-of-Prescription-Pain-Medications-Among-Medical-Cannabis-Patients
- It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis – 2018
- Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort – 2018
- Patterns and correlates of medical cannabis use for pain among patients prescribed long-term opioid therapy. – PubMed – NCBI
- Associations between medical cannabis and prescription opioid use in chronic pain patients – A preliminary cohort study – 2017
- Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems – A Clinical Review – 2015
- Cannabis for the Management of Pain – Assessment of Safety Study (COMPASS) – 2015
Medical Marijuana – Product Evaluation
- The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products – 2018
- Recommended methods for the identification and analysis of cannabis and cannabis products – 2009
- Quality Control of Traditional Cannabis Tinctures – Pattern, Markers, and Stability – 2016
Medical Marijuana –Misc
- A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. – PubMed – NCBI
- Cannabis and cannabis extracts – greater than the sum of their parts? – 2001
- Medical cannabis and mental health: A guided systematic review. 2016 – PubMed – NCBI
- Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. – PubMed – NCBI
- Cannabis-conclusions – 2017 National Academy of Sciences
- Cannabis-chapter-highlights – 2017 National Academy of Sciences
- Cannabis-report-highlights – 2017 National Academy of Sciences
- Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Bene ts of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions?-2004
- Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. – PubMed – NCBI
- Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. – PubMed – NCBI
- Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. – PubMed – NCBI
- Cannabinoids and Cytochrome P450 Interactions. – PubMed – NCBI Pharmacogenetics of Cannabinoids – 2018
- Systematic review of systematic reviews for medical cannabinoids – 2018
- Adverse effects of medical cannabinoids – a systematic review – 2008
- Cannabimimetic effects modulated by cholinergic compounds. – PubMed – NCBI
- Antagonism of marihuana effects by indomethacin in humans. – PubMed – NCBI
- Pharmacokinetics and pharmacodynamics of cannabinoids. – PubMed – NCBI
- Clinical Pharmacodynamics of Cannabinoids – 2004
- Affinity and Efficacy Studies of Tetrahydrocannabinolic Acid A at Cannabinoid Receptor Types One and Two. – 2017
- Quality Control of Traditional Cannabis Tinctures – Pattern, Markers, and Stability – 2016
- Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. – PubMed – NCBI
- Pharmacology of Cannabinoids
- Current-status-and-future-of-cannabis-research-Clin-Researcher-2015
- Taming THC – potential cannabis synergy and phytocannabinoid-terpenoid entourage effects – 2011
- The Cannabis sativa Versus Cannabis indica Debate – An Interview with Ethan Russo, MD – 2016
- Review of the neurological benefits of phytocannabinoids – 2018
Emphasis on Education
Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.
For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.
Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.
For more information, please contact Accurate Clinic.
Supplements recommended by Dr. Ehlenberger may be purchased commercially online or at Accurate Clinic.
Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.
Accurate Supplement Prices
.